About Us
The Department of Genetic Medicine at Weill Cornell leads a dynamic and innovative translational research program, advancing diverse fields such as Genetic Therapy and Personalized Medicine.
Genetic control of wayward pluripotent stem cells and their progeny after transplantation.
| Publication Type | Academic Article |
| Authors | Kiuru M, Boyer J, O'Connor T, Crystal R |
| Journal | Cell Stem Cell |
| Volume | 4 |
| Issue | 4 |
| Pagination | 289-300 |
| Date Published | 04/03/2009 |
| ISSN | 1875-9777 |
| Keywords | Cell Differentiation, Neoplastic Stem Cells, Pluripotent Stem Cells, Stem Cell Transplantation, Transplantation Conditioning |
| Abstract | The proliferative capacity of pluripotent stem cells and their progeny brings a unique aspect to therapeutics, in that once a transplant is initiated the therapist no longer has control of the therapy. In the context of the recent FDA approval of a human ESC trial and report of a neuronal-stem-cell-derived tumor in a human trial, strategies need to be developed to control wayward pluripotent stem cells. Here, we focus on one approach: direct genetic modification of the cells prior to transplantation with genes that can prevent the adverse events and/or eliminate the transplanted cells and their progeny. |
| DOI | 10.1016/j.stem.2009.03.010 |
| PubMed ID | 19341619 |
| PubMed Central ID | PMC3254150 |